Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.38 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818878 | 0.88 | ALB (0.56) | TRPA1ALBKDM1ALMNATP53 | |
| SCHEMBL6833427 | 0.86 | ALB (0.50) | TRPA1ALBKDM1ALMNATP53 | |
| SCHEMBL6834154 | 0.85 | KMT2A (0.49) | ALBMAPTNR1H4NHERF1 | |
| SCHEMBL6833137 | 0.84 | MAP3K5 (0.44) | ALBNR1H4NSD2NHERF1 | |
| SCHEMBL6835708 | 0.84 | CCKAR (0.51) | LMNANHERF1 | |
| SCHEMBL6834385 | 0.83 | SERPINE1 (0.51) | ALBNR1H4NHERF1 | |
| SCHEMBL6710393 | 0.82 | TRPA1 (0.41) | TRPA1KDM1ALMNATP53MAPT | |
| SCHEMBL6830151 | 0.82 | ALB (0.42) | ALBLMNATP53MAPTNR1H4 | |
| SCHEMBL6835688 | 0.82 | GFER (0.45) | ALBLMNATP53NR1H4NSD2 | |
| SCHEMBL6707599 | 0.82 | TRPA1 (0.41) | TRPA1KDM1ALMNATP53MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | TRPA1 377/4885ALB 1417/4885KDM1A 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.